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ABSTRACT
Oligonucleotide-based therapeutics have the capac-
ity to engage with nucleic acid immune sensors to
activate or block their response, but a detailed under-
standing of these immunomodulatory effects is cur-
rently lacking. We recently showed that 2′-O-methyl
(2′OMe) gapmer antisense oligonucleotides (ASOs)
exhibited sequence-dependent inhibition of sensing
by the RNA sensor Toll-Like Receptor (TLR) 7. Here
we discovered that 2′OMe ASOs can also display
sequence-dependent inhibitory effects on two major
sensors of DNA, namely cyclic GMP-AMP synthase
(cGAS) and TLR9. Through a screen of 80 2′OMe
ASOs and sequence mutants, we characterized key
features within the 20-mer ASOs regulating cGAS
and TLR9 inhibition, and identified a highly potent
cGAS inhibitor. Importantly, we show that the fea-
tures of ASOs inhibiting TLR9 differ from those in-
hibiting cGAS, with only a few sequences inhibiting
both pathways. Together with our previous studies,
our work reveals a complex pattern of immunomod-
ulation where 95% of the ASOs tested inhibited at
least one of TLR7, TLR9 or cGAS by ≥30%, which
may confound interpretation of their in vivo func-
tions. Our studies constitute the broadest analysis
of the immunomodulatory effect of 2′OMe ASOs on
nucleic acid sensing to date and will support refine-
ment of their therapeutic development.
INTRODUCTION
RNA-targeting therapeutics based on synthetic oligonu-
cleotides have been gaining interest, with several regulatory
approvals in the US and European Union (1), and multi-
billion license deals from big pharma in recent years (2). To
permit their essential functions related to gene targeting ac-
tivities, oligonucleotides-based therapeutics require both in-
creased affinity for their targets and stabilisation against nu-
clease activities; this can be achieved through the incorpora-
tion of modified nucleotides (e.g. with 2′-O-methyl [2′OMe],
2′-methoxyethyl [2′MOE], 2′-fluoro [2′F], or locked nucleic
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acid [LNA]) as well as modified internucleotide linkages
(e.g. phosphorothioate [PS]).
The intricate relationship between synthetic oligonu-
cleotides and nucleic acids sensors of the innate im-
mune system, which are involved in the early detection of
pathogens, has been known for two decades. For instance,
PS-modified unmethylated ‘CG’ (CpG) containing DNA
oligonucleotides have the potential to activate the DNA
sensor Toll-Like Receptor (TLR) 9 (3,4), but can also block
it in a sequence- and length-dependent manner (5–8). Simi-
larly, 2′OMe modified RNAs block RNA sensing by TLR7
and TLR8 (9,10) and Retinoic Acid Inducible Gene-I (RIG-
I) (11). This knowledge has been important for the de-
sign of oligonucleotide therapeutics that can evade activa-
tion of innate immune sensors, otherwise leading to strong
off-target pro-inflammatory immune responses in patients
(3,12–14). From this perspective, chemical modifications
can have the dual benefit of increasing the targeting efficacy
of the oligonucleotides, while decreasing their immunostim-
ulatory effects.
Nonetheless, it has also been clear for some time that
select PS-modified DNA oligonucleotides (ODN) have
broad immunosuppressive effects (15). This is best exem-
plified with the ‘TTAGGG’ containing PS-ODN A151, in-
volved in the inhibition of TLR9 (6), TLR7 (16), Absent
In Melanoma 2 (AIM2) (17) and cyclic-GMP-AMP syn-
thase (cGAS) (18). These effects are sequence-dependent,
with some PS-DNA ODNs displaying limited immuno-
suppressive activities on individual immune sensors (7,15).
Similarly, 2′OMe oligonucleotides can exhibit sequence-
dependent inhibitory effects on TLR7 and TLR8 sensing
(19). These observations suggest a complex picture of im-
munosuppression by chemically modified oligonucleotides
where sequences dictate their activities on nucleic acid sen-
sors. Since only a handful of ODNs have been studied to
date across different receptors (15,18), a detailed under-
standing of the immunosuppressive sequence determinants
of ODNs is currently lacking. Further, our understanding
of the immunosuppressive effects of oligonucleotides com-
bining base and/or backbone modifications, as is seen in
most oligonucleotide therapeutics approved and in devel-
opment, is non-existent. While it is potentially useful to
generate anti-inflammatory ODNs (20), characterizing the
immunosuppressive effects of therapeutic oligonucleotides
is becoming important to avoid the potential for increased
susceptibility to infection in the large patient populations
beginning to receive ODN therapies (2).
We recently investigated the TLR7 and TLR8 im-
munomodulatory effect of RNase-H1-recruiting gapmer
2′OMe ASOs, which have a central DNA core of 10 nt
flanked by 5 nt of 2′OMe, on a PS backbone (21). Unex-
pectedly, we demonstrated that the majority of the 2′OMe
gapmer ASOs tested were potent inhibitors of TLR7, but
that selected sequences harbouring 2′OMe ‘CUU’ motifs
did not block TLR7 activation (21). Conversely, we found
that TLR8 sensing of the low molecular weight synthetic
ligand Resiquimod (referred to as R848 hereafter), was po-
tentiated by select 2′OMe ASOs, in a sequence-dependent
manner, an observation that aligns with previous findings
with poly-dT PS ODNs (21–23). These findings prompted
us to investigate the broader immunomodulatory effects of
2′OMe ASOs on nucleic sensing, with the aim of defining
the molecular patterns controlling these activities.
In the present study, we focused on the effect of 2′OMe
ASOs on two key innate immune sensors of pathogenic
DNA: cGAS, which detects cytoplasmic DNA in most tis-
sues, and TLR9, which detects endosomal DNA in se-
lect immune cells (20). We demonstrated the sequence-
dependent modulation of both receptors by the ASOs and
identified specific motifs involved in these activities, based
on a panel of 80 2′OMe ASOs. Integration of these results
with those from our previous report allowed us to generate
a broad overview of immunomodulation by 2′OMe ASOs
on RNA (TLR7 or 8) and DNA (cGAS or TLR9) sens-
ing. Specifically, for instance, we have identified a signif-
icant correlation between cGAS and TLR7 immunosup-
pressive effects. Collectively, our studies present the most
comprehensive analysis of the modulation of nucleic acid
sensing by PS ASOs, confirming their prevalent immuno-
suppressive activity. Our studies highlight the need to con-
sider these sequence-dependent activities to avoid misin-
terpreting results and clinical outcomes and to avoid in-
creasing the susceptibility to infection for patients receiving
oligonucleotide-based therapeutics.
MATERIALS AND METHODS
Cell isolation, culture and stimulation
Human primary bone marrow-derived mesenchymal stem
cell (MSCs) from two healthy adult donors (#1129 and
#1980) were purchased from Lonza (#PT-2501) and were
cultured in Dulbecco’s modified Eagle’s medium plus L-
glutamine supplemented with 1× antibiotic/antimycotic
(Thermo Fisher Scientific) and 10% heat-inactivated foetal
bovine serum (referred to as complete DMEM). Culture
media was replaced twice a week and cells were passaged
at 80% confluency and seeded at a density of 2.5 × 103
cells/cm2. These cells were confirmed free from pathogens
and certified to meet MSC criteria as defined by the In-
ternational Society of Cell and Gene Therapy. MSCs used
herein were plated at passage 6–7. Synovial cells were ob-
tained from rheumatoid arthritis (RA) patients who ful-
filled the American College of Rheumatology (ACR) cri-
teria for the classification of RA (24). RA and control pri-
mary fibroblast-like synoviocytes (FLS) were obtained from
surgical specimens of synovial tissue and cultured as previ-
ously described (25). FLS were grown in RPMI 1640 plus L-
glutamine medium (Life Technologies) complemented with
1x antibiotic/antimycotic and 10% heat inactivated foetal
bovine serum (referred to as complete RPMI).
Trex1-mutant mice (used under ANU animal ethics refer-
ence A2018/38) have a single-base mutation in Trex1 lead-
ing to a premature stop codon (Q98X). Homozygous mu-
tant mice have aberrant accumulation of cytoplasmic DNA,
resulting in basal engagement of the cGAS-STING path-
way (Ellyard J.I. and Vinuesa C.G., manuscript in prepara-
tion), similar to that reported in Trex1-deficient mice (26).
Primary bone marrow derived macrophages (BMDMs)
from 3 Trex1-mutant mice were extracted and differentiated
for 6 days in complete DMEM supplemented with L929
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hTLR7-HA, 293XL-hTLR9-HA and HEK-Blue™ hTLR3
stably expressing human TLR7, TLR9 or TLR3 were pur-
chased from Invivogen, and were maintained in complete
DMEM supplemented with either 10 g/ml and 30 g/ml
Blasticidin (Invivogen), for TLR7 or 9 and TLR3 cells,
respectively. HeLa cells, human colorectal cancer HT-29
(kind gift from R. Firestein), human fibroblasts express-
ing SV40 (large and small T antigens) with HRASG12V
(kind gift from E. Sanij (28); referred to as BJ hTERT
SV40T herein), LL171 cells (mouse L929 cells expressing
an IFN-stimulated response element (ISRE)-Luciferase -
kind gift from V. Hornung (29)), and immortalized wild-
type mouse bone marrow macrophages (BMDMs) (30)
were grown in complete DMEM. Human osteosarcoma
MG-63 cells were purchased from ATCC (#CRL-1427)
and grown in ATCC-formulated Eagle’s Minimum Es-
sential Medium, supplemented with 10% heat-inactivated
foetal bovine serum (Thermo Fisher Scientific) and 1×
antibiotic/antimycotic (Thermo Fisher Scientific). Human
acute myeloid leukemia THP-1 and their CRISPR-Cas9
derivatives (cGAS-/- (31), UNC93B1–/– and UNC93B1–/–
reconstituted with UNC93B1 (32)) cells were grown in com-
plete RPMI. THP-1 cells were not differentiated with phor-
bol 12-myristate 13-acetate (PMA) in any experiments, and
rather used in suspension. All the cells were cultured at 37◦C
with 5% CO2. Cell lines were passaged 2–3 times a week and
tested for mycoplasma contamination on a routine basis by
PCR.
For cGAS stimulations, cells were treated for the indi-
cated duration with ASOs, prior to transfection with ISD70
(human cells) or ISD45 (mouse cells) (the ASOs were not
washed off prior to ISD transfection unless otherwise in-
dicated). The cGAS ligands ISD45 (33) and ISD70 (also
known as VACV-70 (34)) (Supplementary Table S1) were
resuspended as follows: 5 l of sense and 5 l of antisense
strands at 10 g/l were added to 90 l PBS under ster-
ile conditions, heated at 75◦C for 30 min, prior to cool-
ing to room temperature and aliquoting (stock at 1 g/1
l). The ISDs were transfected at a concentration of 2.5
g/ml at a ratio of 1 g:1 l with Lipofectamine 2000
in Opti-MEM (Thermo Fisher Scientific). HEK-TLR3,
HEK-TLR7 and HEK-TLR9 were treated with indicated
concentrations of ASOs for 20–50 min, prior to stimulation
with poly(I:C) (Invivogen), R848 (Invivogen), and the Class
B CpG oligonucleotides ODN 2006 (synthesised by IDT
and resuspended in RNase-free TE buffer [Supplementary
Table S1]), respectively. The TLR2/1 agonist, PAM3CSK4
(Invivogen); the TLR4 agonist, lipopolysaccharide (Invivo-
gen); the mouse Sting agonist, DMXAA (Cayman); and
the human STING agonist, (compound #3 from (35), re-
ferred to as GSK herein – kind gift from Cancer Therapeu-
tics CRC, Australia), were used at indicated concentrations.
Aspirin (Sigma-A2093) was resuspended in pure DMEM
to 10 mM, filter sterilised and added to the cells for a fi-
nal concentration of 2 mM. All ASOs were synthesised by
Integrated DNA Technologies (IDT), and resuspended in
RNase-free TE buffer, pH 8.0 (Thermo Fisher Scientific).
ASO sequences and modifications are provided in Supple-
mentary Tables S1 and S2. Cell viability was assessed by
adding 1× fresh resazurin solution to the wells (10X solu-
tion made up with 7 mg resazurin [Sigma] dissolved in 3.5
ml PBS, filter sterilised at 0.2 M) for 4 h, prior to reading
with a Fluostar OPTIMA (BMG LABTECH) plate-reader
(fluorescence: excitation 535 nm, emission 590); wells with
medium only and 1X resazurin were used as blanks.
Luciferase assays
HEK293 cells stably expressing TLR3, 7 or 9 were reverse-
transfected with pNF-B-Luc4 reporter (Clontech), with
Lipofectamine 2000 (Thermo Fisher Scientific), according
to the manufacturer’s protocol. Briefly, 500 000–700 000
cells were reverse-transfected with 400 ng of reporter with
1.2 l of Lipofectamine 2000 per well of a six-well plate,
and incubated for 3–24 h at 37◦C with 5% CO2. Following
transfection, the cells were collected from the six-wells and
aliquoted into 96-wells, just before ASO and overnight TLR
stimulation (as above described). Similarly, the LL171 cells
expressing an ISRE-Luc reporter were treated overnight.
The next day, the cells were lysed in 40 l (for a 96-well
plate) of 1× Glo Lysis buffer (Promega) for 10 min at room
temperature. 15 l of the lysate was then subjected to fire-
fly luciferase assay using 40 l of Luciferase Assay Reagent
(Promega). Luminescence was quantified with a Fluostar
OPTIMA (BMG LABTECH) luminometer.
Beta-galactosidase staining
A -Galactosidase staining assay was performed on FLS
and MSCs treated with ASOs using the Senescence -
Galactosidase Staining kit (New England Biolabs). Briefly,
FLS and MSCs were washed with PBS, fixed and stained
over 24–48 h with X-Gal solution at 37◦C according to the
manufacturer’s protocol. The cells were imaged using in-
verted phase microscopy. Three to 6 images were taken per
condition and analysed with ImageJ, counting the number
of -Galactosidase positive cells (blue) per image (totalling
>100 cells for each condition). The relative proportion of
blue cells per field was calculated for each image.
ASO reverse-transfections
For Figures 1A, 3F and G, ASOs were reverse-transfected
with Lipofectamine 2000. Briefly, a solution of 1.125 l
Lipofectamine 2000 in 25 l Opti-MEM was mixed to a
solution of 1 l of 10 M ASO in 25 l Opti-MEM. Fol-
lowing 20–25 min incubation at room temperature, the re-
sulting 50 l solution was dispensed into a 24-well plate,
and 50 000 to 80 000 cells in 450 l antibiotic-free medium
were added, giving a final ASO concentration of 20 nM per
well. For conditions with 50 and 100 nM ASOs (Figure 3F),
the amount of Lipofectamine was kept constant. Cells were
lysed in 150 l RNA lysis Buffer (ISOLATE II RNA Mini
Kit (Bioline)) after 24 h incubation.
mRNA reverse transcription quantitative real-time PCR (RT-
qPCR)
Total RNA was purified from cells using the ISOLATE
II RNA Mini Kit (Bioline). Random hexamer cDNA was
synthesized from isolated RNA using the High-Capacity
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Figure 1. Sequence-dependent inhibition of cGAS sensing by ASOs. (A) HeLa and HT-29 cells were transfected for 24 h with 20 nM of indicated ASOs
targeted to cGAS (Supplementary Table S1), prior to RNA purification and RT-qPCR analyses. cGAS levels were reported relative to 18S, and normalised
to Mock condition. Data shown represent the median of two independent experiments for each cell line. (B) THP-1 pre-treated overnight with 100 nM
of the indicated ASO, were transfected or not (non-treated [NT]) with 2.5 g/ml ISD70 for 8.5 h and IP-10 levels in supernatants were determined by
ELISA. Data shown are averaged from two independent experiments in biological triplicate (± s.e.m and ordinary one-way ANOVA with Tukey’s multiple
comparison tests to the ‘ISD70 only’ condition, or otherwise indicated pairs of conditions are shown). There was no basal effect of the ASOs on NT cells
(21). (C) HT-29 cells pre-treated overnight with 125, 250 or 500 nM of indicated ASOs, were transfected or not (non-treated [NT]) with 2.5 g/ml of
ISD70 for 24h, and IP-10 levels in supernatants were determined by ELISA. IP-10 levels were normalised to the ‘ISD70 only’ condition, after background
correction with the NT condition. Data shown are averaged from two independent experiments in biological triplicate (± s.e.m. and Mann–Whitney U
tests to the ‘ISD70 only’ condition are shown). (D, E) THP-1 pre-treated overnight with 100 nM of the indicated ASOs, were transfected with 2.5 g/ml of
ISD70 for 7–8 h, and IP-10 levels in supernatants were determined by ELISA. (D) Stimulations and ELISAs were carried out in two independent plates and
the results presented on each axis (with a correlation r = 0.7716, P < 0.0001). Averaged values from both plates are given in Supplementary Table S2. ISD70
only condition is shown in blue. (E) IP-10 levels were normalised to the ‘ISD70 only’ condition, after background correction with NT condition. Data
shown are averaged from three independent experiments in biological triplicate (± s.e.m. and ordinary one-way ANOVA with Tukey’s multiple comparison
tests to the condition ‘ISD70 only’, or otherwise indicated pairs of conditions, which are shown). (F) HT-29 cells pre-treated overnight with 187.5 nM
of indicated ASOs were transfected or not with 2.5 g/ml of ISD70 for 24 h, and IP-10 levels in supernatants determined by ELISA. IP-10 levels were
normalised to the ‘ISD70 only’ condition, after background correction with NT condition. Data shown are averaged from three independent experiments
in biological triplicate (± s.e.m. and ordinary one-way ANOVA with Dunnett’s multiple comparison tests to the condition ‘ISD70 only’ condition are
shown). (G) cGAS–/–, UNC93B1–/– and matched controls with rescued UNC93B1 expression (UNC93B1 WT) THP-1 were pre-treated 6 h with 100 or
250 nM ASOs, and transfected with 2.5 g/ml of ISD70 overnight. GSK (100 nM) and ODN2006 (500 nM) were used as human STING and TLR9
agonists, respectively. IP-10 levels in supernatants were determined by ELISA and normalised to the ‘GSK’ condition, after background correction with
NT condition. Data shown are averaged from three independent experiments in biological triplicate (± s.e.m and ordinary two-way ANOVA with Tukey’s
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to the manufacturer’s instructions. RT-qPCR was carried
out with the Power SYBR Green Master Mix (Thermo
Fisher Scientific) on the HT7900 and QuantStudio 6
RT-PCR system (Thermo Fisher Scientific). Each PCR
was carried out in technical duplicate and human or mouse
18S was used as the reference gene. Each amplicon was
gel-purified and used to generate a standard curve for the
quantification of gene expression (used in each run). Melt-
ing curves were used in each run to confirm specificity of





















Human IP-10 and IFN- levels were measured using super-
natants from the different cultures and were quantified us-
ing IP-10 (BD Biosciences, #550926) or IFN- (PBL assay
science, #41415-1) ELISA kits respectively, according to the
manufacturers’ protocols. Tetramethylbenzidine substrate
(Thermo Fisher Scientific) was used for quantification of
the cytokines on a Fluostar OPTIMA (BMG LABTECH)
plate-reader.
cGAS in vitro assay and cGAMP ELISA
0.8 g of recombinant full-length human cGAS (Cayman,
#22810) was used per single reaction in a 200 l volume
with 80 mM Tris–HCl (pH 7.5), 200 mM NaCl, 20 M
ZnCl2, 20 mM MgCl2, 0.25 mM GTP (Thermo Fisher Sci-
entific #R0441) and 0.25 mM ATP (Thermo Fisher Sci-
entific #R0461), with 20 g of ISD70 (freshly annealed at
1 g/l in PBS), and 2 l C2-Mut1/A151 diluted in TE
buffer (to get 0.5, 2 or 10 M ODN concentration in 200
l). After 40 min at 37◦C, 2.5 mM EDTA was added to each
tube to stop the enzymatic reaction and the samples were ei-
ther snap frozen and stored at –80◦C or directly processed
for cGAMP ELISA. cGAMP levels were measured with the
DetectX Direct 2′,3′-Cyclic GAMP Enzyme Immunoassay
Kit (Arbor Assays), according to the manufacturer’s proto-
col. Briefly, 50 l of in vitro reactions were added per well to
the kit microplate with 50 l Assay buffer, 25 l conjugate,
and 25 l Antibody per well, prior to a minimum of 2 h in-
cubation. The standards were prepared with serial-dilution
in Assay buffer. Quantification of cGAMP levels was per-
formed on a Fluostar OPTIMA (BMG LABTECH) plate-
reader at 450 nm.
Statistical analyses
Statistical analyses were carried out using Prism 8 (Graph-
Pad Software Inc.). Every experiment was repeated a min-
imum of two independent times (except the ASO screens –
Figures 1D and 4D, conducted in single experiments, but
for which key ASOs were validated in a minimum of two
independent experiments). One-way and two-way analyses
of variance (ANOVA) were used when comparing groups
of conditions, while two-tailed unpaired non-parametric
Mann-Whitney U tests or unpaired two-tailed t-tests were
used when comparing pairs of conditions. Symbols used: *
P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 0.0001 and ‘ns’
is non-significant.
RESULTS
Sequence-dependent effects of 2′OMe gapmer ASOs on
cGAS sensing
cGAS has recently emerged as an essential sensor of cytoso-
lic DNA deriving from pathogens and damaged endoge-
nous nucleic acids (20). Upon activation by DNA, cGAS
drives the formation of cyclic GMP-AMP (cGAMP), which
binds to stimulator of interferon (IFN) genes (STING)
and promotes transcriptional induction of IRF3 responsive
genes, including CXCL10 (IP-10) and IFNB1. Since it insti-
gates deleterious immune responses linked to a wide range
of diseases, various approaches are being investigated cur-
rently to therapeutically target cGAS (36–40). We originally
hypothesised that strategies relying on the down-regulation
of cGAS mRNA could provide therapeutic alternatives to
chemical inhibitors of cGAS, which have been pursued in
many other studies (36–40). To study this possibility, we
designed a panel of 11 2′OMe gapmer ASOs (ASO1 to
ASO11) that targeted the mRNA of human cGAS and
tested their effects in HeLa cells and HT-29 cells, which
endogenously express cGAS (Figure 1A and Supplemen-
tary Table S1). Transfection of the ASOs led to a sequence-
dependent decrease of cGAS mRNA, although variable be-
tween the two cell lines, with ASO2 having a 30–50% im-
pact, while ASO3/ASO4 robustly failed to decrease cGAS
expression (Figure 1A).
We next tested the functional effect of our panel of ASOs
on undifferentiated monocytic THP-1 cells, upon overnight
uptake of the naked ASOs (Figure 1B). In contrast to
the down-regulation signature seen in HeLa and HT-29
cells, ASO2 was the most potent oligonucleotide block-
ing IP-10 production after transfection of the synthetic 70-
bp interferon stimulating DNA (ISD70), which acted as
the cGAS ligand (34). This observation was reproduced in
cGAS/STING-competent epithelial HT-29 cells (41) where
overnight incubation with 125 nM of ASO2 (but not ASO4,
ASO10 or ASO11) blunted ISD70-induced IP-10 produc-
tion (Figure 1C). Critically, however, increased doses of
ASO4, ASO10 and ASO11 also blocked ISD70-induced
IP-10 production, when used at 250 (ASO4/ASO10) or
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account their differing effects on cGAS mRNA target-
ing (Figure 1A), the dose-dependent inhibitory effect of
ASO4/ASO10/ASO11 on ISD70-sensing strongly suggests
it was independent of cGAS mRNA targeting, but rather re-
lated to a competitive effect on cGAS sensing of ISD70; this
aligns with the effect observed for PS-ODN A151 on cGAS
sensing (18). Our hypothesis that ASOs have a direct effect
on cGAS function was consistent with the observation that
ASO11 increased ISD70-sensing at low doses, but was also
inhibitory at higher doses, which may relate to the binding
of the ASO to the third DNA binding domain of cGAS, in-
creasing its enzymatic activity at low dose (42) (Figure 1C).
Since ASO2 inhibited ISD70-sensing at a lower concen-
tration than the other ASOs, we posited that select mo-
tifs may increase the inhibitory effect of 2′OMe gapmer
ASOs on ISD70-sensing of cGAS. To define this further,
we screened a library of 80 2′OMe ASOs, designed to tar-
get the CDKN2B-AS1 and LINC-PINT transcripts (Sup-
plementary Table S2 and (21)), in THP-1 transfected with
ISD70 (Figure 1D). While none of these ASOs targeted the
cGAS mRNA, 23 out of 80 decreased ISD70-driven IP-10
production by >40% (Figure 1D and Supplementary Ta-
ble S2). A few highly inhibitory ASOs were selected from
the screen for validation in THP-1 (C2, E10 and F2 ASOs)
and HT-29 cells (C2 and E10 ASOs) transfected with ISD70
(Figure 1E, F). Overnight pre-treatment with C2 robustly
inhibited ISD70-dependent IP-10 production in both cell
models, while a significant effect of E10 was seen only in
THP-1 cells (noting a reduction of 25% with this sequence in
HT-29 cells). Importantly, C2 was a more potent inhibitor
than ASO2 (Figure 1E) and A151 (Figure 1E, F).
We have recently shown that 2′OMe gapmer ASOs are
spontaneously taken up by undifferentiated THP-1 and
can modulate endosomal TLR7/8 sensing (21). To exclude
a putative contribution of endosomal TLRs upon ISD70
transfection, we next tested the effect of C2 and ASO11 in
THP-1 cells lacking cGAS (31) or UNC93B1 (32), the lat-
ter being devoid of TLR7/8 and 9 sensing. While cGAS-
deficient and UNC93B1-deficient cells similarly produced
IP-10 upon stimulation with a synthetic human STING ag-
onist (35), cGAS-deficient THP-1 cells also lacked respon-
siveness to ISD70 transfection (Figure 1G). Conversely, we
observed a dose-dependent inhibitory effect of C2 on ISD70
sensing in UNC93B1-deficient and matched wild-type cells,
not seen with ASO11 (Figure 1G), ruling out a contribution
of endosomal TLRs in the effects of C2 on ISD70 sensing.
Collectively these results demonstrate a capacity for 2′OMe
gapmer ASOs to inhibit cGAS sensing of transfected DNA,
in a sequence-dependent manner.
Identification of a 2′OMe motif controlling cGAS inhibition
Having shown that ASO2, C2 and E10 were potent in-
hibitors of ISD70 sensing in THP-1, we next sought to de-
fine whether select motifs in these ASOs were involved in
their inhibitory activities. MEME motif discovery analy-
sis (43) performed on the three sequences identified a pu-
tative enriched motif in the 5′ half of C2 and 3′ half of
both ASO2 and E10, with four highly conserved bases (Fig-
ure 2A and Supplementary Figure S1A). To test the im-
portance of these four bases, we first designed two variants
of C2, substituting two (C2-Mut1) or four (C2-Mut2) of
these bases (Figure 2A). The bases used to replace those
in the motif were arbitrarily chosen, and could equally de-
crease or increase the inhibitory activity. In accordance with
our hypothesis that these specific bases made a direct con-
tribution to inhibition, dose-response analyses of the C2
mutants on ISD70-driven IP-10 production in HT-29 cells
showed increased inhibitory activity for both ASOs at 125
and 250 nM compared to the parent C2 ASO (this de-
crease being significant for C2-Mut1 at 125 nM; Figure
2B). Similarly, C2-Mut1 was significantly more inhibitory
on the ISD45-driven interferon stimulated response element
(ISRE)-luciferase than was C2 and ASO2 in mouse LL171
cells (Figure 2C). Conversely, in LL171 cells the 20-mer PS
oligonucleotide (dT20) did not inhibit ISD45 sensing even
at 600 nM, confirming the sequence-specific nature of the
ASO inhibition in mouse cells (Figure 2C). In parallel, hav-
ing shown that C2 was a more potent inhibitor than ASO2
(Figure 1E), we designed mutants of ASO2 harbouring the
5′ region of C2 (ASO2up), or a mutant of the four conserved
bases (ASO2down – Figure 2A). While not significant in
HT-29 cells, the trend was that ASO2up was a more po-
tent inhibitor of ISD70-driven IP-10 production than ASO2
(at 125 nM). Conversely, ASO2down significantly increased
IP-10 production at 62.5 and 125 nM, aligning with what
was seen with ASO11 in HT-29 cells (Figure 2D).
Since two base mutations of C2 in C2-Mut1 signifi-
cantly increased ISD70-driven IP-10 inhibition, we next de-
signed a series of four C2-Mut1 mutants (C2-Mut1v1 to
C2-Mut1v4) with base permutations to define whether the
inhibition seen with C2-Mut1 could be enhanced further
(Figure 2E). We also designed hybrid ASOs fusing the 5′
half of C2-Mut1 to the 3′ half of ASO2up (C2-ASO2-A)
or ASO2down (C2-ASO2-B). Analyses of these sequences
in HT-29 (Figure 2F) and THP-1 (Figure 2G) revealed
that C2-Mut1 was robustly the most inhibitory sequence of
ISD70 sensing and was significantly more potent than its
mutant C2-Mut1v3. Interestingly, C2-ASO2-A, which con-
tains two fused inhibitory motifs (that of C2-Mut1 in the
5′ half, and that of ASO2up/C2 in the 3′ half), had a sim-
ilar potency to that of C2-Mut1, indicating that duplicat-
ing the inhibitory motif in the 3′ end region of the ASO
did not significantly enhance the inhibition (Figure 2F, G).
Nonetheless, in THP-1 cells, C2-ASO2-B was significantly
less inhibitory than C2-ASO2-A and ASO2 down was sig-
nificantly less inhibitory than ASO2up, confirming that 3′
end regions could also play a role in the inhibition of ISD70
sensing (Figure 2G).
cGAS inhibition by a minimal mGmGmUATC motif
We next asked whether the 2′OMe chemical modification of
gapmer ASOs was at play in their effect on cGAS. In both
mouse LL171 and human THP-1 cells, the inhibitory effect
of C2-Mut1 was significantly decreased in a C2-Mut1 ana-
logue in which the 2′OMe ends were replaced by DNA bases
on a PS-backbone (referred to as C2-Mut1-PS) (Figure 2H,
I and Supplementary Table S1). In addition, MEME motif
discovery on the 10 most inhibitory ASOs from our screen
(Figure 1D and Supplementary Table S2) revealed that
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Figure 2. Identification of a highly potent inhibitor of cGAS sensing. (A) Top: sequence alignments of cGAS inhibitors and identification of important
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aligned with that of C2 and C2-Mut1, which was predomi-
nantly overlapping with their 2′OMe 5′ end (Supplementary
Figure S1B). Interestingly, one of these sequences, ‘[LINC-
PINT]103′ (referred to as ASO103), was part of a family of
sequences with single base increments (Supplementary Ta-
ble S2 and Figure 2J). Within this series, ASO103 was the
only sequence significantly inhibiting ISD70-driven IP-10
production in THP-1 cells, further supporting the idea that
the 5′-end location and 2′OMe modifications were likely es-
sential to the ASO inhibitory function (Figure 2K).
The data collected so far demonstrated that long (i.e.
6–16 h) pre-incubation with 2′OMe gapmer led to inhibi-
tion of ISD sensing by cGAS. To tease out the role of the
pre-incubation on the inhibitory activity of the ASOs, we
compared the effect of C2-Mut1 pre-incubated for 6 h in
LL171 cells, with or without a wash prior to the transfec-
tion of ISD45. We also tested the effect of ASOs that were
added a short time prior to the transfection of ISD45 (∼20
min). While pre-incubation of the ASOs for a shorter dura-
tion did not impact their inhibitory effect on ISD45-driven
ISRE-Luc expression, the addition of a washing step signif-
icantly blunted inhibition (Figure 2L). These findings sug-
gested that the ASOs were somewhat co-transfected with
the liposome containing ISD. Accordingly, increased intra-
cellular fluorescent puncta of ASO2-Cy3 were observed fol-
lowing ISD70 transfection of HT-29 cells (Supplementary
Figure S2), altogether suggesting that the ASOs competed
with ISD for cGAS sensing intracellularly.
Relying on this shorter ASO pre-incubation, we next
sought to confirm the core motif modulating cGAS inhi-
bition in C2-Mut1. We started from a 20-mer homopoly-
meric sequence of dCs on a PS backbone (dC20), to which
the minimal 2′OMe containing terminal 5′ mGmGmU-
ATC motif of C2-Mut1 was added (referred to Mut1-dC)
(Figure 2E). Mut1-dC was significantly more inhibitory
than its precursor dC20 on ISD sensing in LL171 and
THP-1 cells (Figure 2M, N). In addition, the two base-
mutations (mCmGmUTTC) in Mut1v3-dC lacked signifi-
cant inhibitory activity in both cell models (Figure 2M, N).
Together with our previous observations, these results es-
tablish that the minimal mGmGmUATC motif is sufficient
to confer cGAS inhibition to a PS-modified homopoly-
meric sequence, with a predominant role for the two bases
previously identified.
Sequence-specific inhibition of cGAS activity by C2-Mut1
Having identified C2-Mut1 as our most potent 2′OMe ASO
inhibitor of cGAS, we performed dose-response analyses to
determine its IC50 in our THP-1 model and to compare
it to that of A151 (18). Based on IP-10 driven production
after ISD70 transfection, we determined that the IC50 of
C2-Mut1 was 56 nM compared to 165 nM for A151 (Fig-
ure 3A). This greater inhibitory activity of C2-Mut1 over
that of A151 on DNA sensing was confirmed looking at the
production of IFN-, which was blocked with C2-Mut1 at
125 nM, while only reduced by ∼50% for A151 at that dose
(Figure 3B). It is also noteworthy that treatment of the cells
with C2-Mut1 did not significantly impact cell viability in
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
mutations at selected positions of the MEME motif (mutations are highlighted in yellow). (B, D) HT-29 cells pre-treated overnight with indicated doses of
ASOs (500, 250, 125, 62.5 nM), were transfected or not with 2.5 g/ml of ISD70 for 24 h and IP-10 levels in supernatants were determined by ELISA. IP-10
levels were normalised to the ‘ISD70 only’ condition, after background correction to the NT condition. Data shown are averaged from two (D) or three
(B) independent experiments in biological triplicate (± s.e.m and ordinary two-way ANOVA with Tukey’s multiple comparison tests relative to C2 [B] or
ASO2 [D] conditions, are shown; comparisons were not significant between the ASOs for 250 and 500 nM). (C) Mouse LL171 cells were treated for 6 h with
indicated amount of ASOs (200, 400, 600 nM) prior to overnight stimulation with 2.5 g/ml ISD45. Cells were lysed and ISRE-Luc levels were analysed by
luciferase assay the next day. ISRE-luciferase levels were normalised to the ‘ISD45 only’ condition, after background correction with NT condition. Data
shown are averaged from two independent experiments in biological triplicate (± s.e.m and Mann-Whitney U tests are shown). (E) Top: sequence alignments
of C2-Mut1 variants; C2-ASO2-A and C2-ASO2-B have the 3′ ends from ASO2up and ASO2down underlined. Bottom: variants of the homopolymer
dC20; 2′OMe bases are in pink and the cGAS inhibitory motif underlined. (F) HT-29 cells pre-treated overnight with 187.5 nM indicated ASOs were
transfected or not with 2.5 g/ml of ISD70 for 24 h and IP-10 levels in supernatants were determined by ELISA. (G) THP-1 pre-treated overnight with
100 nM indicated ASOs were transfected with 2.5 g/ml of ISD70 for 24 h and IP-10 levels in supernatants determined by ELISA. (F, G) IP-10 levels
were normalised to the ‘ISD70 only’ condition, after background correction with the NT condition. Data shown are averaged from three independent
experiments in biological triplicate (± s.e.m. and ordinary one-way ANOVA with Tukey’s multiple comparison tests relative to condition ‘ISD70 only’, or
otherwise indicated pairs of conditions are shown). (H) LL171 cells were treated for 6 h with 200 nM ASOs prior to overnight stimulation with 2.5 g/ml
ISD45. Cells were lysed and ISRE-Luc levels were analysed by luciferase assay the next day. ISRE-luciferase levels were normalised to the ‘ISD45 only’
condition, after background correction with the NT condition. Data shown are averaged from three independent experiments in biological triplicate (±
s.e.m. and ordinary one-way ANOVA with Dunnett’s multiple comparison tests to the ‘ISD70 only’ condition are shown). (I) THP-1 cells treated for 6 h
with 100 nM C2-Mut1, or 100, 250, 500 nM of C2-Mut1-PS were transfected with 2.5 g/ml of ISD70 overnight. IP-10 levels were normalised to the ‘ISD70
only’ condition, after background correction with the NT condition. Data shown are averaged from two independent experiments in biological triplicate
(± s.e.m and Mann-Whitney U tests to the ‘ISD70 only’ condition are shown). (J) Sequences of [LINC-PINT] ASOs 101–116, showing the location of the
inhibitory GGUCCC motif (in pink) from ASO103 identified by MEME (see E and Supplementary Figure S1B). The yellow region highlights the DNA
moiety of the gapmers. (K) THP-1 pre-treated overnight with 100 nM indicated [LINC-PINT] ASOs, were transfected with 2.5 g/ml of ISD70 for 7.5 h and
IP-10 levels in supernatants were determined by ELISA. IP-10 levels were normalised to the ‘ISD70 only’ condition, after background correction with the
NT condition. Data shown are averaged from three independent experiments in biological triplicate (± s.e.m and one-way ANOVA with Dunnett’s multiple
comparison tests to the ‘ISD70 only’ condition are shown). (L, M) LL171 cells were treated for 6 h or 20 min with 200 nM ASOs prior to being ‘washed’
or not (L), or treated with 50, 100 or 200 nM ASOs for 20 min (M), and stimulated overnight with 2.5 g/ml ISD45. Cells were lysed and ISRE-Luc levels
were analysed by luciferase assay the next day. ISRE-luciferase levels were normalised to the ‘ISD45 only’ condition, after background correction with the
NT condition. Data shown are averaged from two (L) or three (M) independent experiments in biological triplicate (± s.e.m. and one-way ANOVA with
Tukey’s multiple comparison tests to the ‘ISD45 only’ condition (L), or Mann-Whitney U tests to the ‘ISD45 only’ condition (M), or otherwise indicated
pairs of conditions, are shown). (N) THP-1 pre-treated for 40 min with 250 nM indicated ASOs, were transfected overnight with 2.5 g/ml of ISD70 and
IP-10 levels in supernatants were determined by ELISA. Data shown are averaged from three independent experiments in biological triplicate (±s.e.m. and
ordinary one-way ANOVA with Dunnett’s multiple comparison tests to the ‘ISD70 only’ condition, and a Mann-Whitney U test comparing Mut1-dC and
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Figure 3. Sequence-dependent inhibition of cGAS function. (A, B) THP-1 pre-treated 6 h with indicated doses (500, 250, 125, 62.5, 31.25 nM) (A) or 125
nM (B) of C2-Mut1 or A151 oligonucleotides, were transfected with 2.5 g/ml of ISD70 overnight, and IP-10 (A) or IFN- (B) levels in supernatants were
determined by ELISA. IP-10 (A) and IFN- (B) levels were normalised to the ‘ISD70 only’ condition, after background correction with the NT condition.
(A, B) Data shown are averaged from three independent experiments in biological triplicate (± s.e.m. and ordinary two-way ANOVA with Sidak’s multiple
comparison tests relative to A151 are shown [A] or ordinary one-way ANOVA with Tukey’s multiple comparison tests relative to condition ‘NT’, or
otherwise indicated pairs of conditions are shown [B]). MG-63 (C) or mouse immortalised BMDMs (D) were pre-treated or not with 500 nM of C2-
Mut1 for 6 h prior to stimulation with 2.5 g/ml ISD (ISD70 for MG-63, ISD45 for BMDMs), LPS (1 g/ml), GSK (100 nM), PAM3C (100 ng/ml),
ODN1826 (500 nM), or DMXAA (50 g/ml) overnight. IP-10 (C and D) and TNF- (D) levels in supernatants were determined by ELISA. (C) Data
were normalised to the ‘GSK’ condition, after background correction to the NT condition. Data shown are averaged from two independent experiments
in biological triplicate (± s.e.m and Mann-Whitney U tests are shown). (D) IP-10 levels were normalised to the DMXAA condition, while TNF- levels
were normalised to the LPS condition. Data shown are averaged from three independent experiments in biological triplicate (± s.e.m and Mann-Whitney
U tests are shown). (E) Recombinant cGAS protein was incubated in vitro with 2.3 M ISD70 with or without (NT) increasing concentrations of ASOs
(0.5, 2 and 10 M) for 40 min. The reaction was stopped with EDTA and cGAMP levels were analysed by ELISA. Data were normalised to the condition
A151 2 M. Data shown are averaged from three independent experiments run in technical duplicate on the ELISA (± s.e.m and a Mann-Whitney U
test is shown). (F) BJ hTERT SV40T cells were transfected overnight with an increasing amount of indicated ASO (20, 50, 100 nM), or 2 mM aspirin
(ASP), prior to RNA purification. Expression of the panel of 3 human IFN-driven genes was analysed by RT-qPCR. Expression of the indicated genes was
reported against to 18S expression and further normalised to the average of the ‘Mock’ condition. Data shown represent the average of three independent
experiments conducted in biological duplicate (± s.e.m and Mann-Whitney U tests are shown). (G) Trex1-mutant primary BMDMs from three individual
homozygous mice were transfected with 50 nM ASOs (or lipofectamine only, ‘Mock’) for 20 h, prior to RNA purification. Expression of the panel of three
mouse IFN-driven genes was analysed by RT-qPCR. Expression of the indicated genes was reported against to 18s expression and further normalised to
the average of the ‘Mock’ condition. Data shown represent the average of three mice conducted in biological duplicate (± s.e.m. and Mann–Whitney U
tests are shown). * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 0.0001, ns: non-significant.
our assays in THP-1 and HT-29 cells (Supplementary Fig-
ure S3).
In human MG-63 cells and immortalised mouse bone
marrow derived macrophages (BMDMs), a 6 h pre-
incubation with high dose C2-Mut1 (500 nM) did not sig-
nificantly affect IP-10 production driven by lipopolysaccha-
ride (LPS–TLR4 ligand) or STING synthetic agonists, al-
though the pre-incubation significantly impacted ISD sens-
ing (Figure 3C, D). Similarly, C2-Mut1 did not impact pro-
duction of TNF- upon treatment with LPS, PAM3CSK4
(TLR2/1 ligand) or DMXAA (mouse Sting agonist) (Fig-
ure 3D). Nonetheless, C2-Mut1 pre-incubation significantly
decreased sensing of the CpG ODN 1826, which acti-
vates mouse Tlr9, as revealed by dampened TNF- pro-
duction in immortalised BMDMs (Figure 3D). This is con-
sistent with our previous report that PS-2′OMe ASO can
impact endosomal sensing by TLRs such as TLR7/8 in
phagocytes (21), but indicates that C2-Mut1 is not broadly
inhibiting non-nucleic acid sensing pathways such as
TLR1/2/4, nor acting at the level of downstream signalling
cascades.
In vitro, cGAS has previously been shown to be bound
and weakly activated by single stranded ISD45 (44), lead-
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‘inactive’ competitors of double stranded ISD. To directly
assess this, recombinant cGAS was incubated in vitro with
2.3 M (0.1 g/l) of ISD70 in the presence of increasing
amounts of C2-Mut1 or A151 (0.5, 2 and 10 M). Criti-
cally, while both PS-ODNs similarly reduced cGAMP pro-
duction driven by ISD70 at 0.5 M, the inhibitory activ-
ity of C2-Mut1 was significantly greater than that of A151
(about 2-fold more) at 2 M (Figure 3E). Under these spe-
cific conditions in vitro, C2-Mut1 was therefore able to dis-
place more molecules of ISD70 than A151, suggesting C2-
Mut1 had stronger affinity for cGAS than did A151. To-
gether with our cell-based assays, these observations sup-
port that C2-Mut1 acts as an inactive competitor of ISD70
binding to cGAS.
C2-Mut1 inhibits constitutively active cGAS signalling
Since our experiments to this point strictly relied on cGAS
sensing of exogenously transfected ISD, we next investi-
gated the effects of our ASOs on cell models with con-
stitutive cGAS activation. We first compared the dose-
dependent effect of C2-Mut1 and C2-Mut1v3 transfected
in human BJ hTERT fibroblasts stably expressing SV40T
and RASG12V (28), which display a basal level of con-
stitutive cGAS activation (45). Transfected C2-Mut1 was
significantly more potent than its two nucleotide variant
C2-Mut1v3 in inhibiting expression of several interferon
stimulated genes (ISGs) (IFIT1, IFIT2 and IFI44) consti-
tutively expressed in these cells (46) and had an effect com-
parable to aspirin treatment that blocks cGAS activity (47)
(Figure 3F). Secondly, overnight transfection of C2-Mut1
and C2-Mut1-v3 significantly decreased the basal expres-
sion of two out or three ISGs (Rsad2 and Ifit1) in primary
mouse bone marrow derived macrophages (BMDMs) from
Trex1-mutant mice (Q98X – see Material and Methods),
which exhibit accumulated cytoplasmic DNA and constitu-
tive cGAS-STING signalling (Figure 3G) (20). Conversely,
transfection of a similar dose of A151 failed to inhibit these
ISGs (Figure 3G).
cGAS activation has been shown recently to play an im-
portant role in the paracrine propagation of senescence
between cells (48,49). As such, senescence-associated -
galactosidase (SAB) was strongly decreased during the ex-
pansion of primary mouse fibroblasts from cGas-deficient
mice (48). We therefore decided to investigate the capacity
of C2-Mut1 to inhibit spontaneous engagement of cGAS-
STING signalling, in pre-senescent primary fibroblast-like
synoviocytes (FLS) and primary bone marrow-derived mes-
enchymal stem cells (MSCs). For this purpose, we grew the
primary cells in the presence of 1–5 M C2-Mut1 ASO
(passively taken up by the cells by gymnosis) for one to
two weeks. While a large proportion of cells were senes-
cent in non-ASO treated cells after this period (based on
-galactosidase positive staining, seen in up to ∼40–50%
of the cells), senescence was strongly reduced in C2-Mut1-
treated FLS cells and MSCs (Supplementary Figure S4A,
S4B). Further experiments in another set of FLS cells
showed that C2-Mut1 was more potent in inhibiting SAB
than its PS only variant C2-Mut1-PS, or its mutant C2-
Mut1v3. Similarly, C2-Mut1 was a more potent inhibitor
of SAB than A151 (Supplementary Figure S4C), aligning
with the concept that this activity pertained to its increased
inhibition of cGAS.
Collectively, these results demonstrate that C2-Mut1 sig-
nificantly inhibits constitutive cGAS sensing of endogenous
cytoplasmic DNA, in a sequence-dependent manner.
Sequence-dependent TLR9 inhibition by 2′OMe gapmer
ASOs
Having demonstrated the sequence-dependent modulation
of cGAS sensing of DNA by 2′OMe gapmer ASOs, we
next turned to their effect on DNA sensing by TLR9,
with the aim of providing a broad picture of their impact
on DNA sensing in human cells. As such, while there is
ample evidence for sequence-dependent TLR9 modulation
with select PS-ASOs (3,7), including A151 (6), the impact
of 2′OMe moieties in the context of PS-gapmer ASOs, is
not defined. We recently demonstrated that 2′OMe gapmer
ASOs did not frequently activate TLR9, with the exception
of ‘T’ rich sequences (21). To characterise whether 2′OMe
gapmer ASOs instead led to inhibition of DNA sensing by
TLR9, as indicated with our results in BMDMs with C2-
Mut1 (Figure 3D), we tested our panel of 11 cGAS ASOs
on TLR9 sensing of CpG ODN2006 in HEK cells express-
ing human TLR9 (HEK-TLR9 hereafter) and a NF-B lu-
ciferase reporter. We included PS-ODN A151 and IRS957,
which have been reported to inhibit TLR9, along with their
respective controls, C151 and IRS661 (6,7)). Several ASOs
significantly inhibited TLR9 sensing of ODN2006, includ-
ing ASO2, 4, 5, 6, 7, 8, 9, 10 (Figure 4A). However, ASO2,
IRS957 and A151 were the only oligonucleotides reducing
NF-B luciferase induction by more than 80%. Our previ-
ous observation that ASO11, which lacked the capacity to
inhibit TLR9 but strongly potentiated TLR8 in HEK cells
(21), indicated that the sequence-specific effects seen here
were not related to uptake of the ASOs, but rather due a
competitive effect of specific motifs on ODN2006 sensing
by TLR9.
To investigate further the sequence determinants of
TLR9 inhibition by 2′OMe gapmer ASOs, we initially
assessed the effect of ASO2 3′-end mutants (ASO2up
and ASO2down) and ASO11 mutants where the 5′ or 3′
2′OMe regions had been swapped with those of ASO2
(ASO11Mut1 and ASO11Mut2) in HEK-TLR9 cells (Fig-
ure 4B, C). The four-base substitutions in the 3′-end of
ASO2down significantly reduced TLR9 inhibition, unlike
those in ASO2up, indicating the inhibitory effect was par-
tially dependent on the sequence of the 3′ half of ASO2.
Critically, substitution of the ASO11 5′-end 2′OMe region
with that of ASO2 (ASO11Mut2), but not its 3′-end re-
gion (ASO11Mut1), conferred significant TLR9 inhibition
to ASO11, suggesting that the 5′-end of ASO2 is also at play
in its regulatory effect on TLR9 (Figure 4C).
To gain further insights into the sequence-dependent in-
hibition of TLR9 sensing of DNA by 2′OMe gapmer ASOs,
we next tested our panel of 80 2′OMe ASOs in HEK-TLR9
cells, (Figure 4D and Supplementary Table S2). We ob-
served that only 8 out of the 80 ASOs inhibited TLR9 by
more than 50% (Supplementary Table S2), and ASO2 re-
mained the most potent ASO tested. MEME motif discov-
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Figure 4. Sequence-dependent TLR9 inhibition. (A, C) HEK-TLR9 cells expressing a NF-B-luciferase reporter were treated with 500 nM indicated ASOs
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cant enrichment in three ASOs of a ‘GGCCTC’ motif also
present in ASO2, and a ‘A’-rich central region in 5 out of
the 10 ASOs (Figure 4E, F and Supplementary Figures S1C,
S1D). Accordingly, when we compared the central DNA re-
gions of the 16 most and least inhibitory ASOs in the TLR9
screen, we observed a significantly higher proportion of cen-
tral ‘As’ in the more potent TLR9 inhibitory sequences (Fig-
ure 4G and Supplementary Table S2).
Closer analyses of two ASOs families from the screen
with single base increments also pointed to an important
role for 5′ 2′OMe ‘CUU’ motifs in TLR9 inhibition (Sup-
plementary Table S2). Validation of the first family, re-
ferred to as the ‘CDKN2B-AS1’ series (ASO2133-2139),
suggested that addition of a 5′-end terminal ‘CUU’ mo-
tif in ASO2139 significantly increased TLR9 inhibition
(Figure 4H, I). Aligning with this observation, analyses
of the ‘LINC-PINT’ series of ASOs (ASO108-ASO116),
also harbouring 5′ or 3′ ‘CUU’ motifs, demonstrated that
‘CUU/CUT’ motifs present in the 5′ 2′OMe region of the
ASOs (ASO112-115) were associated with a significant in-
crease in TLR9 inhibition compared to ASO108-110 con-
taining such 2′OMe ‘CUU’ motifs in their 3′ end (Figure
4I, J).
To define further the role of 2′OMe ‘CUU’ motifs on
the modulation of TLR9 sensing, we next used an addi-
tional panel of 2′OMe ASOs targeting the mRNA of HPRT
(Figure 4K and (21)). While 5′-end terminal ‘CUU’ motifs
in ASO [HPRT]551 and 660 were associated with >60%
inhibition of TLR9, addition of a single 5′-end terminal
base to the ‘CUU’ motif (‘ACUU’) in ASO661 significantly
limited inhibition (Figure 4K, L). Conversely, ASO662,
with its ‘CACUUU’ 5′-end 2′OMe region displayed the
strongest inhibition of this series of ASOs, although this
may also be related to a contribution of its ‘UUUUC’ 3′-
end (uniquely present in this sequence in this series). Inter-
estingly, ASO666 also strongly inhibited TLR9, while not
displaying any ‘CUU’ motif and only differing by two bases
from ASO665, which was only poorly inhibitory (Figure
4K, L). Nonetheless, these results are only suggestive of a
role for selected motifs in the modulation of TLR9 inhibi-
tion, and need to be taken with caution given the putative
impact of base increments on 2′OMe regions, which could
confound the interpretation of results. Taken together, these
findings demonstrate a complex regulation of TLR9 inhibi-
tion by 2′OMe gapmer ASOs, including preferential con-
tributions from central (preferentially ‘A’ rich) and 5′-end
2′OMe regions.
In contrast with these findings, we have recently reported
that 2′OMe ‘CUU’ motifs could help mitigate TLR7 in-
hibition by 2′OMe gapmer ASOs (21), suggesting an in-
verse relationship between the modulation of these two sen-
sors. We therefore analysed the correlation of the effect
of the 80 ASOs on TLR9 and TLR7 inhibition (21), pre-
sented in Figure 4M. There was no correlation between
the activities of the ASOs on TLR7 and TLR9, exem-
plified with ASO[LINC-PINT]108, ASO109, ASO116 and
A10 which had limited effect on TLR9, and TLR7, unlike
ASO[CDKN2B-AS1]2139, which did not inhibit TLR7 but
strongly inhibited TLR9.
C2-Mut1 is a potent inhibitor of human cGAS, TLR7 and
TLR3 but not TLR9
Having generated immunomodulatory profiles for our
panel of 80 2′OMe ASOs on TLR7/TLR8 (21), TLR9
and cGAS, we generated a bubble chart to visualise the
correlation of inhibition of DNA sensing by cGAS and
TLR9, while also incorporating data on TLR7 inhibition
and TLR8 potentiation (Figure 5A and Supplementary Ta-
ble S2). There was no significant correlation between TLR9
and cGAS inhibition, illustrated by the example that C2,
the most potent cGAS inhibitor in our screen did not in-
hibit TLR9 (Figure 5A). This observation was validated in
HEK-TLR9 cells with C2 and its mutants C2-Mut1 and C2-
ASO2-A. While the C2 mutants were significantly better in-
hibitors of TLR9 than their parent ASO, their inhibitory
effect on TLR9 sensing was limited compared to that of
ASO2 or A151 (Figure 5B).
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
B-luciferase levels were normalised to the ‘ODN2006 only’ condition, after background correction with the NT condition. Data shown are averaged from
two (A) or three (C) independent experiments in biological triplicate (± s.e.m. and ordinary one-way ANOVA with Dunnett’s multiple comparison tests
to the ‘ODN2006 only’ condition [A] or Mann–Whitney U tests [C] are shown). (B) ASO2 and ASO11 sequence mutants. ASO11Mut1 and ASO11Mut2
contain the 3′ and 5′ end of ASO2, respectively. (D) HEK-TLR9 cells expressing a NF-B-luciferase reporter were treated with 500 nM indicated ASOs for
45 min prior to stimulation or not with 200 nM ODN2006. NF-B-luciferase levels were measured after overnight incubation. NF-B-luciferase levels were
normalised to the ‘ODN2006 only’ condition, after background correction with the NT condition. Stimulations and luciferase assays were carried out in
two independent plates and the results are presented on each axis (with a correlation r = 0.7909, P < 0.0001) (averaged data are provided in Supplementary
Table S2). The 10 most potent ASOs (reference position in the plate is given as per Supplementary Table S2) are highlighted on the plot. ASOs with ≤50%
reduction of TLR9 activity at 500 nM are highlighted with blue shading. (E) Bottom: MEME pictogram of the relative frequency of bases constituting the
TLR9 inhibitory motif. Top: alignment of the sequences enriched with the motif identified as per Supplementary Figure S1D. The reference position in the
plate is given as per Supplementary Table S2. (F) Alignment of the sequences enriched with ASO2 motif (Supplementary Figure S1C). (G) The central 10
DNA bases of the top and bottom 16 TLR9 inhibitors from the 80 ASOs screened (see Supplementary Table S2) were analysed for base content. The violin
plots show the distribution of the cumulative number of each central base for both ASO populations. Ordinary two-way ANOVA with Sidak’s multiple
comparison tests (between top and bottom populations) are shown. (H, J, L) HEK-TLR9 cells expressing a NF-B-luciferase reporter were treated with
500 nM indicated ASOs for 45 min prior to stimulation or not (non-treated [NT]) with 200 nM ODN2006. NF-B-luciferase levels were measured after
overnight incubation. NF-B-luciferase levels were normalised to the ‘ODN2006 only’ condition, after background correction with the NT condition.
Data shown are averaged from three independent experiments in biological triplicate (± s.e.m). One-way ANOVA with Dunnett’s multiple comparison
tests to the ‘ASO2138’ condition (H), or the ‘ASO108’ condition (J), are shown. (L) One-way ANOVA with Tukey’s multiple comparison tests relative
to the condition ‘661’, or otherwise indicated pairs of conditions are shown. (I, K) Sequence alignments showing the ‘CUU’ motifs in families of closely
related ASOs; the yellow region highlights the DNA moiety of the gapmers. (M) Correlation of TLR7 and TLR9 inhibition based on 80 ASOs (used at 100
nM for TLR7, and 500 nM for TLR9). Percentages of NF-B-luciferase levels relative to the conditions ‘R848 without ASO’ (for TLR7) or ‘ODN2006
without ASO’ (for TLR9) are averaged from biological duplicate (averaged data are provided in Supplementary Table S2) (with a correlation r = 0.05256,
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Figure 5. The broad immunosuppressive effects of 2′OMe ASOs. (A) Bub-
ble graph showing the relationship between cGAS, TLR9, TLR7 inhibi-
tion, and TLR8 potentiation (based on the data from Supplementary Table
S2 and (21)), for 80 ASOs. For TLR7 and TLR9, percentages of NF-B-
luciferase levels relative to the conditions ‘R848 without ASO’ (for TLR7)
or ‘ODN2006 without ASO’ (TLR9) are shown (the size of the bubbles
reflects TLR7 signalling strength). For TLR8, fold increases relative to
the condition ‘R848 without ASO’ are shown, using a 4 colour-scale. For
cGAS, percentages of IP-10 production relative to the condition ‘ISD70
only’ are shown. Selected ASOs are indicated: the reference position in the
plate is given as per Supplementary Table S2. (B) HEK-TLR9 cells express-
ing a NF-B-luciferase reporter were treated with 500 nM indicated ASOs
for 30–45 min prior to stimulation or not (non-treated [NT]) with 200 nM
ODN2006. NF-B-luciferase levels were measured after overnight incu-
bation. NF-B-luciferase levels were normalised to the ‘ODN2006 only’
condition, after background correction with NT condition. Data shown
are averaged from three independent experiments in biological triplicate
(± s.e.m and one-way ANOVA with Tukey’s multiple comparison tests rel-
ative to condition ‘ODN2006 only’, or otherwise indicated pairs of condi-
As shown in Figure 5A, the patterns of immunomodu-
lation on these sensors was highly variable with only a few
ASOs inhibiting TLR7, TLR9 and cGAS (e.g. C4, C6 and
H7) (Supplementary Table S2). Nonetheless, there was a
significant correlation between cGAS and TLR7 inhibition
(Figure 5C), with the strongest inhibitors of cGAS also dis-
playing strong TLR7 repression (e.g. C2, E10, F2, H7; Fig-
ure 5C). Consistent with this, the most potent cGAS in-
hibitor, C2-Mut1, was also a strong inhibitor of R848 sens-
ing by TLR7, with an IC50 of 44 nM, against 132 nM for
A151 (Figure 5D). Critically, only 4 ASOs in our screen (i.e.
5%) did not inhibit any of TLR7, TLR9 or cGAS by >30%
(highlighted in red in Figure 5A, and in yellow in Supple-
mentary Table S2), demonstrating that most 2′OMe ASOs
have immunosuppressive effects.
Unlike their inhibitory effect on TLR7, we recently dis-
covered that select 2′OMe gapmer ASOs could potentiate
TLR8 sensing of R848, presenting potential therapeutic op-
portunities in immuno-oncology (21). Interestingly, TLR8
potentiation was also inversely correlated with cGAS inhi-
bition, with the best TLR8 potentiators lacking cGAS in-
hibition (e.g. G7, A9, D9, G9) (Figure 5E). Accordingly C2
was a weak potentiator of TLR8, but select ASOs may be
able to inhibit cGAS while potentiating TLR8 sensing, as
seen with the example of ASO2 (Figure 1 and (21)).
Finally, we tested the effect of our panel of 11 cGAS
ASOs (including IRS661, IRS957, A151 and its mutant
C151) on the sensing of untransfected double stranded
RNA (polyI:C) by human TLR3 sensing in HEK 293 cells
stably expressing human TLR3 (HEK-TLR3) and a NF-B
luciferase reporter (it should be noted that these cells are not
responsive to the amount of untransfected polyI:C we used,
through RIG-I or MDA5). While all 2′OMe gapmer ASOs
used at 500 nM along with IRS661 and IRS957 blocked
polyI:C sensing, A151 and C151 only partially reduced
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
tions are shown). (C) Correlation of TLR7 and cGAS inhibition based on
80 ASOs (used at 100 nM for TLR7 and cGAS). Percentages of NF-B-
luciferase levels relative to the conditions ‘R848 without ASO’ (for TLR7)
or percentages of IP-10 production relative to the condition ‘ISD70 only’
are shown (with a significant correlation r = 0.2780, P = 0.0125). Selected
ASOs are indicated; the reference position in the plate is given as per Sup-
plementary Table S2. (D) HEK-TLR7 cells expressing a NF-B-luciferase
reporter were treated with the indicated concentration of ASOs (500, 250,
125, 62.5, 31.25 nM) for 30–50 min prior to stimulation with 1 g/ml R848.
NF-B-luciferase levels were measured after overnight incubation. NF-
B-luciferase levels were normalised to the ‘R848 only’ condition, after
background correction with the NT condition. Data shown are averaged
from three independent experiments in biological triplicate (± s.e.m. and
ordinary two-way ANOVA with Sidak’s multiple comparison tests relative
to A151 are shown). (E) Correlation of TLR8 potentiation and cGAS in-
hibition based on 80 ASOs (used at 500 nM for TLR8 and 100 nM cGAS).
Fold increases of NF-B-luciferase levels relative to the conditions ‘R848
without ASO’ (for TLR8) or percentages of IP-10 production relative to
the condition ‘ISD70 only’ are shown (with a significant correlation r =
0.2879, P = 0.0096). Selected ASOs are indicated; the reference position in
the plate is given as per Supplementary Table S2. (F) HEK-TLR3 cells ex-
pressing a NF-B-luciferase reporter were treated with indicated concen-
trations of C2-Mut1 (1000, 500, 250, 125, 62.5, nM) or A151 (753, 376.5,
188.25, 94.125 or 47.0625 nM) for 30–50 min prior to stimulation with 0.5
g/ml pIC. NF-B-luciferase levels were measured after overnight incuba-
tion. NF-B-luciferase levels were normalised to the ‘pIC only’ condition,
after background correction with NT condition. Data shown are averaged
from three independent experiments in biological triplicate (± s.e.m.). * P
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polyI:C-dependent TLR3 activation in these cells (Supple-
mentary Figure S5A). Sequence-specific inhibition of TLR3
was more visible with 100 nM ASOs, where only ASO5 re-
tained significant inhibition of polyI:C sensing (Supplemen-
tary Figure S5B). Direct comparison of the inhibitory ef-
fect of C2-Mut1 and A151 on TLR3 sensing in HEK-TLR3
cells confirmed the stronger inhibition of C2-Mut1, with an
IC50 of 62 nM for C2-Mut1 and an IC50 greater than 750
nM for A151 (Figure 5F). Collectively these results demon-
strate that C2-Mut1 is a potent inhibitor of human cGAS,
TLR7 and TLR3, but a weaker inhibitor of TLR9.
DISCUSSION
There is growing evidence that the cGAS-STING path-
way not only has roles in detecting viral and bacterial cy-
tosolic DNA (50,51), but also acts a sensor of cellular in-
tegrity, activated by damaged nuclear DNA (45,48,49,52),
and cytoplasmic mitochondrial DNA (53), to facilitate
clearance of damaged cells by immune cells (48,49). Criti-
cally, cGas/Sting-deficiency has been shown to be protec-
tive against many diseases in pre-clinical animal models
(including in Parkinson’s disease, amyotrophic lateral scle-
rosis, acute pancreatitis, macular degeneration, myocardial
infarction, alcohol-related liver disease, and polyarthritis
(54–56)), providing strong rationale for the development of
cGAS inhibitors as new therapeutic avenues for these dis-
eases.
Most of the strategies reported to date to inhibit cGAS-
STING signalling have focussed on the development of
small molecules inhibiting cGAS enzymatic activity (36–
40,47,57,58), with a propensity to target cGAS systemically
rather than in specific tissues. Conversely, our approach has
been to develop therapeutic ASOs that could be directed
to modulate cGAS levels in selected tissues. While initially
screening 2′OMe ASOs targeted to the mRNA of human
cGAS, we discovered a disconnect between the ASOs that
decreased cGAS mRNA expression and those inhibiting
cGAS activation by transfected immunostimulatory DNA.
Hypothesising that some of our PS-2′OMe ASOs were act-
ing as competitive inactive ligands for cGAS, as was the
case with the PS-ODN A151 (18), we screened a panel of 80
2′OMe ASOs targeted to two long non-coding RNAs, un-
related to cGAS signalling. These analyses confirmed that
inhibition of cGAS relied on sequence-dependent features
of the ASOs, independent of cGAS mRNA targeting.
In vitro, we showed that our most potent ASO, C2-
Mut1, competes with double stranded DNA to restrict
cGAMP synthesis by cGAS, aligning with the proposed
mechanism of action of A151 (18). However, since C2-
Mut1 was a more potent inhibitor of cGAMP synthesis
than A151, we propose that C2-Mut1 has a stronger affinity
for cGAS; although this warrants confirmatory biochemi-
cal analyses. Importantly, C2-Mut1 was also a strong in-
hibitor of mouse cGas, unlike other small molecule an-
tagonists that display species-specific activities (39). How-
ever C2-Mut1 did not impact activation of the downstream
cGAMP sensor STING, upon stimulation with its specific
agonists (DMXAA in mouse cells (59), and GSK#3 in
human cells (35)). In addition, C2-Mut1 did not impact
sensing of non-nucleic acid sensors TLR2/1 and TLR4.
This confirms further that it does not act at the level of
downstream signalling adaptors shared between these path-
ways, which control the production of cytokines such as IP-
10. We also extended our findings to models where cGAS
is spontaneously engaged by endogenous cytosolic DNA,
rather than transfected ISD. As such, we demonstrated
that transfection of C2-Mut1 in BJ hTERT SV40T fibrob-
lasts or Trex1 mutant primary macrophages, causing basal
engagement of the pathway (45), reduced basal expres-
sion of interferon-stimulated genes (ISGs); this occurred
in a sequence-dependent manner, comparable to what is
observed with the cGAS inhibitor, aspirin (47). Finally,
we showed that culture of primary human cells with high
concentrations of C2-Mut1 for 1 to 2 weeks, robustly re-
duced the number of senescent positive cells, in a sequence-
specific manner. Recent evidence suggests that cGAS is
engaged upon destabilisation of the nuclear membrane in
senescent cells (48,49), resulting in a paracrine amplifica-
tion of senescence (48), consistent with our prior observa-
tion of cGAMP-like activity in senescent joint fibroblast-
like synoviocytes (60). The present results indicate that
spontaneous uptake of the ASOs, also known as gymnotic
delivery, is able to block engagement of cGAS in senes-
cent cells. These findings are in agreement with the previ-
ous demonstration that gymnotic delivery of the PS-ODN
A151 reduced basal ISG signature in TREX1-deficient
macrophages (18). Although further studies would be war-
ranted to confirm direct involvement of cGAS inhibition by
C2-Mut1 in the decreased senescence observed here, these
observations support the idea that spontaneous uptake of
C2-Mut1 is biologically relevant to limit senescence.
Direct comparison between our most potent cGAS in-
hibitor ASO (C2-Mut1) and A151, confirmed that pre-
treatment with both molecules inhibited sensing of trans-
fected immunostimulatory DNA, to significantly reduce
IP-10 production in a dose-dependent manner, along with
IFN- levels. However, C2-Mut1 was more potent than
A151 in cells and in vitro, blocking IP-10 and IFN- pro-
duction at a concentration of ∼125 nM in our assays. Stein-
hagen et al. recently demonstrated that A151 competed
against double stranded DNA for binding cGAS, in cells
and cellular extracts (18), but did not provide a detailed
study of the sequence determinants involved in this effect,
beyond the demonstration that the C151 mutant (which
contains 16 mutations compared to A151) did not inhibit
cGAS. In this manuscript we demonstrate that cGAS inhi-
bition by DNA-containing PS-ASOs is intrinsically depen-
dent on their sequence. Most importantly, we have identified
a minimal 5′-end [mGmGmUATC] highly potent cGAS in-
hibitory motif, the activity of which can be impacted by as
few as two nucleotide substitutions (as seen with Mut1v3
sequences). Our studies therefore provide proof-of concept
that 2′OMe ODNs can be rationally designed to inhibit
cGAS. Although duplication of the inhibitory motif in C2-
ASO2-A did not robustly increase cGAS inhibition in our
assays, we note that the duplicated motif did not contain the
correct 2′OMe pattern, which is essential to the activity of
C2-Mut1 (as shown with C2-Mut1-PS). Further studies will
help define whether other sequence variations could help
improve the cGAS inhibitory activity of C2-Mut1. As re-
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against brain injury, oligonucleotides-based inhibition of
cGAS can present novel therapeutic avenues, by leveraging
their unique capacity to inhibit additional immune path-
ways (61). Importantly, A151 used at 15 mg/kg intraperi-
toneally (i.p.) led to cGAS inhibition in vivo (61). Given that
select ASOs such as C2-Mut1 are more potent inhibitors of
cGAS than A151, and that a dosage of 5–15 mg/kg ASO
i.p. is commonly used in pre-clinical studies, it is therefore
possible that gene targeting ASOs used in vivo trigger unin-
tended cGAS inhibition.
When broadly considering the off-target inhibition of
cGAS by 2′OMe ASOs as a class of molecules, we note that
only 13 out of 80 ASOs decreased cGAS activity by >50%
at the dose used in our screen, and we found several in-
hibitory sequences harbouring a [A/G]GUC[U/C]C motif
overlapping with their 5′ 2′OMe end. Although this motif
can be useful to identify cGAS inhibitory ASOs, it is clear
that some sequences are inhibiting cGAS independent of
this motif (e.g. C4, E6 or H7 – Supplementary Table S2 and
Supplementary Figure S1B). Nevertheless, we found that
the least inhibitory sequences in our screen exhibited an en-
riched 5′ or 3′ end ‘CCUUCU’ motif, which may help select-
ing ASOs with limited cGAS inhibitory effects (Supplemen-
tary Figure S1E). This approach warrants further valida-
tions. Based on the data currently at hand, we recommend
avoiding 2′OMe ASOs exhibiting a 5′ [A/G]GUC[U/C]C
motif, and rather favour those with a 3′ end ‘CCUUCU’
to avoid unintended cGAS inhibition. Interestingly, a few
ASOs, such as ASO11, potentiated cGAS sensing when
used at low concentrations in HT-29 and LL171 cells. While
this observation could be due to a potentiation of trans-
fection efficiency of liposome-encapsulated ISD70 by select
ASOs, it could also be due to the binding of such ASOs
to the third DNA binding domain of cGAS, which facili-
tates oligomer formation and increases its enzymatic activ-
ity (42). While additional studies would be required to de-
fine their mode of action, it is clear that select 2′OMe ASOs
can potentiate cGAS sensing when used at low doses, rais-
ing the possibility that these molecules instigate off-target
inflammation in cells where the pathway is basally active.
In addition to their effect on cytoplasmic cGAS, we
present here the first detailed analysis of the impact of
2′OMe gapmer ASOs on endosomal TLR9 inhibition,
based on over 100 ASOs. Since A151 is a potent TLR9
inhibitor, we were interested to define whether cGAS and
TLR9 modulation by 2′OMe ASOs correlated. Nonethe-
less, our analyses of 80 2′OMe ASOs did not find any signif-
icant correlation between the effect of the ASOs on TLR9
and cGAS inhibition. Based on our best human TLR9 in-
hibitor, ASO2, and its associated mutants, we demonstrated
a direct involvement of its 5′ 2′OMe end in sequence-specific
TLR9 inhibition, which conferred inhibition to the other-
wise non-inhibitory ASO11. We note, however, that muta-
tions of 4 bases over the 3′-half of ASO2 could also re-
duce inhibition. Motif enrichment analyses from our screen
also revealed a potential role for ‘A’-rich central DNA
regions in TLR9 inhibition. Given the importance of 5′
2′OMe regions, we sought to identify motifs that condition
TLR9 inhibition and discovered that ASOs with a termi-
nal 5′ ‘CUU/CUT’ motif were often more inhibitory than
closely related sequences. Yet, as shown with the case of
ASO[HPRT]661, other sequence determinants can impact
the activity of such 5′ ‘CUU’ motifs on TLR9 sensing, un-
derlining the complexity of the ASO determinants affecting
TLR9 function.
Overall, human TLR9 sequence-dependent inhibition by
2′OMe ASOs was mostly limited, as only 20 out of 80 ASOs
inhibited TLR9 by more than 40% in our screen. How-
ever, dose-response analyses of ASO2 demonstrated it could
still block TLR9 activity when using half the concentration
of molecules of the TLR9 agonist ODN2006, indicating
a strong potential antagonist effect of some 2′OMe ASOs
(Supplementary Figure S6). CpG ODN are generally used
at around 1–10 mg in humans, suggesting the capacity of
select 2′OMe ASOs to block TLR9 in vivo when used at a
therapeutic dose greater than 1 mg.
We have previously recommended the selection of 2′OMe
‘CUU’ motifs to limit TLR7 inhibition, when designing
ASOs (21). In light of the inhibitory effects of such 5′ ‘CUU’
motifs on TLR9, it appears that selection of ASOs with
3′ ‘CUU’ motifs may be preferable to limit TLR7 inhi-
bition, without increasing TLR9 inhibition. Nevertheless,
the stark differences in TLR9 inhibition seen between very
closely related sequences with 5′ ‘CUU/CUT’ motifs (e.g.
with ASO661 and ASO662 or ASO115 and ASO116), sug-
gest that mitigation of TLR9 inhibition could be achieved
by limited sequence modification of the ASOs – for instance,
by shifting the ASO by one base. We also note that potential
discrepancies may exist between species regarding TLR9
inhibition by 2′OMe ASOs, since C2-Mut1 was a much
stronger inhibitor in mouse macrophages. Mechanistically,
we speculate that 2′OMe ASOs inhibit TLR9 by binding
to it directly and competing with other agonistic DNA se-
quences. Although warranting further validation, this mode
of action is supported by our observation that select 2′OMe
ASOs were able to elicit a mild TLR9 activation on their
own (21). However, it is also possible 2′OMe ASOs indi-
rectly modulate cGAS/TLR9 sensing through other mech-
anisms such as an inhibitory effect on nucleases (e.g. DNase
II), which should be investigated in further studies.
Finally, relying on our previous results regarding TLR7
and TLR8 modulation by 2′OMe ASOs, we performed
a comprehensive comparison of the regulatory effects of
2′OMe ASOs on RNA and DNA sensing in human cells on
our panel of 80 ASOs. Interestingly, TLR7 inhibition cor-
related with that of cGAS, as exemplified with C2-Mut1,
which was also a very potent TLR7 inhibitor (with an IC50
3 times lower than that of A151). TLR8 potentiation was
inversely correlated to cGAS inhibition, with high potentia-
tors of TLR8 often displaying low cGAS inhibition (as seen
with ASO [LINC-PINT]108 in Supplementary Table S2),
suggesting that the rational design of gene targeting ASOs
that can potentiate TLR8 sensing without inhibiting TLR7
and cGAS signalling may be achievable (21).
Critically, our findings suggest that it may be extremely
challenging to generate 2′OMe gapmer ASOs that do not
inhibit any of these three nucleic acids sensors (i.e. TLR7,
TLR9 and cGAS). Based on our screens, we found that 95%
of the ASOs decreased sensing by at least one of these three
sensors by more than 30% and 2′OMe ASOs may have fur-
ther sequence-specific suppressive effects on other nucleic
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In conclusion, we demonstrate here that 2′OMe gap-
mer ASOs can be potent inhibitors of DNA sensing by
human cGAS and TLR9, complementing our recent find-
ings that these molecules can inhibit TLR7 sensing (21).
Paving the way for the design of further highly potent
oligonucleotide-based cGAS inhibitors, we identified the
most potent cGAS-inhibiting oligonucleotide reported to
date, while defining the motif regulating its activity. Al-
though our detailed analyses of the sequence-dependent ef-
fects of 2′OMe ASOs on TLR7, TLR9 and cGAS sens-
ing may help design ASOs that circumvent inhibition by
these receptors, our findings indicate that only a limited
number of molecules have the features to achieve this. This
has important implications for the functional characteriza-
tion and therapeutic development of ASOs, for which differ-
ent immunosuppressive effects between tested and control
ASO sequences may lead to the misinterpretation of results.
Whether similar immunosuppressive effects can be seen for
gapmer ASOs relying on different chemistries remains to be
defined, but our previous analyses on TLR7 sensing with
LNA and 2′MOE (21), along with the broad immunosup-
pressive effects of the PS-ODN A151, suggest that the PS-
DNA moiety found in all gapmer ASOs plays a critical role
in immune inhibition - independent of the chemistries used
in the 5′ and 3′ regions of the gapmers. Finally whether other
key nucleic acid sensors such as AIM2 or Retinoic Acid
Inducible Gene-I (RIG-I) can also be impacted by 2′OMe
ASOs remains to be defined. There is, however, prior evi-
dence that PS-ODN can inhibit AIM2 (17) and that 2′OMe
moieties can modulate RIG-I sensing (11), indicating that
the immunosuppressive effects of ASOs are even broader
than considered here.
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30. Ferrand,J., Croft,N.P., Pépin,G., Diener,K.R., Wu,D., Mangan,N.E.,
Pedersen,J., Behlke,M.A., Hayball,J.D., Purcell,A.W. et al. (2018) The
use of CRISPR/Cas9 gene editing to confirm congenic
contaminations in host-pathogen interaction studies. Front. Cell.
Infect. Microbiol., 8, 87.
31. Mankan,A.K., Schmidt,T., Chauhan,D., Goldeck,M., Höning,K.,
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